US 12,186,288 B2
Double targeted constructs to affect tumor kill
John W. Babich, New York, NY (US); James M. Kelly, Ithaca, NY (US); Alejandro Amor-Coarasa, Ithaca, NY (US); and Shashikanth Ponnala, Ithaca, NY (US)
Assigned to Cornell University, Ithaca, NY (US)
Filed by Cornell University, Ithaca, NY (US)
Filed on Jun. 19, 2020, as Appl. No. 16/906,956.
Application 16/906,956 is a continuation of application No. 16/246,422, filed on Jan. 11, 2019, granted, now 10,716,772.
Application 16/246,422 is a continuation of application No. 15/630,808, filed on Jun. 22, 2017, granted, now 10,179,117.
Claims priority of provisional application 62/353,735, filed on Jun. 23, 2016.
Prior Publication US 2021/0137860 A1, May 13, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07C 275/16 (2006.01); A61K 31/17 (2006.01); A61K 31/19 (2006.01); A61K 51/04 (2006.01); A61K 51/10 (2006.01); C07B 59/00 (2006.01); C07F 7/22 (2006.01); G01N 33/574 (2006.01); G01N 33/58 (2006.01); G01N 33/60 (2006.01)
CPC A61K 31/17 (2013.01) [A61K 31/19 (2013.01); A61K 51/0402 (2013.01); A61K 51/1072 (2013.01); C07B 59/001 (2013.01); C07C 275/16 (2013.01); C07F 7/2208 (2013.01); G01N 33/57434 (2013.01); G01N 33/57492 (2013.01); G01N 33/58 (2013.01); G01N 33/60 (2013.01); C07B 2200/05 (2013.01); G01N 2500/04 (2013.01)] 2 Claims
 
1. A compound that is

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.